乾癬性関節炎を含む脊椎関節炎に対する疾患就職薬の臨床開発パイプライン2023: 臨床試験のシステマティックレビュー
RMD Open. 2023;9(3):e003279 doi 10.1136/rmdopen-2023-003279 https://pubmed.ncbi.nlm.nih.gov/37507210/
This systematic review identified DMARDs evaluated for axSpA and PsA, distinguishing between csDMARDs, tsDMARDs, and bDMARDs. The review pinpointed twenty-six distinct targeted therapies currently in clinical development; 18 therapies for axSpA and 15 therapies for PsA.
Trials retrieved from databases (N=3574) filtered through research terms to identify DMARDs developed for spondyloarthritis, ankylosing spondylitis, and psoriatic arthritis; 9 csDMARDs (5 withdrawn, 1 in development, and 3 marketed), 37 bDMARDs (10 withdrawn, 16 in development, and 11 marketed) and 17 tsDMARDs (5 withdrawn, 9 in development, and 3 marketed) were identified.
The review demonstrated an unmet need in developing strategies or biomarkers to aid clinicians in making informed treatment decisions.
Keywords:
